On October 16, 2018, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (stock code: 300760, stock abbreviation: Mndray Bio-Medical) held its listing ceremony at SZSE. After the ceremony, the company’s directors, supervisors and senior executives participated in the training held by our Department for ChiNext Market Compliance: “Lecture 1 Listed Companies’ Integrity and Compliance”. Mindray Bio-Medical is publicly offering 121.6 million shares at 48.8 yuan per share and raising funds of 5.934. billion yuan. The post-public-offering share capital of Mindray Bio-Medical is 1,215,691,266 in total.

Mindray Bio-Medical principally engages in the research and development, manufacturing, marketing and service of medical devices. It has become China’s largest and global leading provider of medical equipment and solutions, with its products covering the three major fields of life information and support, in vitro diagnosis, and medical imaging. This Shenzhen-based company’s products and solutions have been widely applied in more than 190 countries and regions in Asia, Europe, the Americas and other major areas. In 2017, its operating income reached 11.174 billion yuan with the net profit of 2.589 billion yuan.

At the 19th CPC National Congress, it has been proposed the “Healthy China” Strategy. Medical device industry concerns people’s life and health safety and is a strategic emerging industry of the country’s key support. Also, it is knowledge, technology and fund intensive and greatly influenced by a country’s industrial development level. As China’s economic scale and quality improve, the industry in China is in the stage of quick development. In recent years, China has introduced a series of practical and effective policies and measures to enhance the innovation capacity and industrialization level of high-end medical device sector, with the priority in promoting the new technology breakthroughs and market-oriented application of companies.

As a core institution of capital market and key platform for resource allocation, SZSE is fully devoted to serving the national innovation-driven development strategy and earnestly promoting the implementation of the “Healthy China Strategy”. Mindray Bio-Medical values technical innovation, closely follows clinical demands and has products covered in about 110,000 medical agencies and over 99% hospitals of grade A class 3 in China, helping medical institutions improve medical conditions, lower medical costs and afford quality medical services. With its landing on SZSE, Mindray Bio-Medical will help form a sound demonstration effect, play a guiding role, and drive the standard development of China’s medical equipment industry, thus further satisfying people’s life service needs.

Next, SZSE will continue to take the guidance of Xi Jinping Thought on Socialism with Chinese Characteristics for a New Era, carry to greater depth the guiding principles of the 19th CPC National Congress and follow the CSRC leadership so that it will fully play the platform functions of a multi-tiered capital market. In so doing, it will support the development of strategic emerging industries, the implementation of “Healthy China Strategy”, and listed companies’ provision of quality, all-round and full life cycle service equipment and applications to the people.